Healthpeak Properties stock barely budged, up less than 1% to around US$21.79, even though the earnings story was all about stronger cash generation. For a real estate investment trust, funds from operations is what matters, and Healthpeak reported adjusted funds from operations of US$0.46 per share in the quarter with total revenue of US$771.6m.

The market reaction looks muted compared with that core cash figure and a raised full year adjusted funds from operations guidance range. Investors appear cautious and focused on past volatility, even as the latest numbers point to a firmer earnings base.

Love Healthpeak Properties' firmer funds from operations but still uneasy about past volatility in the stock price? You can review our short list of REITs and income stocks with more resilient cash profiles in the 79 resilient stocks with low risk scores.

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$771.6m vs. US$694.3m (higher period on period)
• Net Income, Q2 2026 vs. Q2 2025: US$52.7m vs. US$31.6m (higher period on period)
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.08 vs. US$0.05 (higher period on period)
• Funds From Operations (FFO), Q2 2026 vs. Q2 2025: US$319.0m vs. US$303.6m (higher period on period)

Prefer clear charts instead of another wall of earnings tables and footnotes? See Healthpeak Properties' full financial picture with an easy visual read on its funds from operations trend, valuation, and more in the company report for Healthpeak Properties.

Healthpeak Bull Case Tied To Cash And Leasing Wins

Bulls argue Healthpeak Properties can use its outpatient, lab and senior housing focus to grow cash generation while recycling capital without losing control of core assets. Q2 results line up with that script in several places. Adjusted FFO of US$0.46 per share and higher guidance of US$1.73 to US$1.77 per share for 2026 indicate a firmer earnings base today, not just a story about tomorrow.

The Brookfield joint venture was a key test. Healthpeak raised about US$1b, kept 51% ownership and full operating control of 86 outpatient buildings, which matches the claim that it can crystallize value yet still drive operations. On the ground, leasing is doing the heavy lifting. Outpatient tenant retention is near 80%, cash re-leasing spreads are around +5%, occupancy is rising in both outpatient and lab, and Janus Living revenue and EBITDA growth all support the idea that operating modernization and scale are translating into real portfolio-level milestones.

Reveal where the surface looks calm, but the multi year models start to disagree on Healthpeak Properties' path, and see what the street is quietly building in for the next few years with the analyst estimates for Healthpeak Properties.

Healthpeak Bears Still Watching Credit And Concentration

The core worry around Healthpeak Properties is that concentrated exposure to smaller biotech tenants, a tight development pipeline and refinancing needs could crack funds from operations once growth cools. Q2 does not fully settle that. Life science occupancy of 78.5% is still well below outpatient levels and only modestly higher than year end 2025, so the feared vacancy and concession risk has not been cleared. Leasing wins and raised adjusted FFO guidance to US$1.73 to US$1.77 per share help, yet do not show how these assets perform through a real funding squeeze for private biotech.

On development execution, management highlights active leasing and projects sourced from existing relationships, but there is no hard update on pre leasing thresholds or build cost inflation on the current pipeline. The conservative 4.7x net debt to EBITDA and US$4.1b liquidity blunt near term balance sheet risk, although refinancing sensitivity still remains largely untested.

After a quarter that still leaves life science occupancy at 78.5% and refinancing largely untested, it is worth asking if these pressures are isolated or early signs of something more structural. Review the full risk analysis for Healthpeak Properties which shows 4 important warning signs

Stay Ahead With Healthpeak Properties Insights

If Healthpeak Properties' stronger funds from operations but uneven life science occupancy has your attention, register for free with Simply Wall St and add the stock to your Watchlist to track price against fair value and wait for a setup that fits your plan. Once you are invested, keep your decisions grounded in data by using the Portfolio Command Center to surface only the key events that really matter to your holdings. For a wider angle on Healthpeak Properties and similar stocks, tap into the crowd’s thinking through the Community and see how other investors are reacting. That way you can spot emerging catalysts and risks early and give yourself a better chance of staying ahead of the market.

Seeking Fresh Alternatives Beyond Healthpeak Properties

Market windows move fast. Fresh ideas can start a breakout, build momentum and then be gone before you have even caught the first move. Scan these under the radar for now stocks and act now.

• Spot cash rich compounders before momentum stories go mainstream by running the 51 high quality undervalued stocks while they are still priced as if nothing has changed and get in early.
• Track where essential infrastructure quietly builds strength by checking the 36 power grid technology and infrastructure stocks. These grid and technology players are still flying under most radars, so be prepared to act decisively.
• Identify the next wave of automation demand by screening the 35 robotics and automation stocks while valuations still look reasonable and before capital concentrates in the same few stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.